MX366134B - Angiotensina en el tratamiento de condiciones cerebrales. - Google Patents

Angiotensina en el tratamiento de condiciones cerebrales.

Info

Publication number
MX366134B
MX366134B MX2015003968A MX2015003968A MX366134B MX 366134 B MX366134 B MX 366134B MX 2015003968 A MX2015003968 A MX 2015003968A MX 2015003968 A MX2015003968 A MX 2015003968A MX 366134 B MX366134 B MX 366134B
Authority
MX
Mexico
Prior art keywords
angiotensin
treating brain
brain conditions
conditions
methods
Prior art date
Application number
MX2015003968A
Other languages
English (en)
Other versions
MX2015003968A (es
Inventor
Franklin Richard
Original Assignee
Tarix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarix Pharmaceuticals Ltd filed Critical Tarix Pharmaceuticals Ltd
Publication of MX2015003968A publication Critical patent/MX2015003968A/es
Publication of MX366134B publication Critical patent/MX366134B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Hematology (AREA)
  • Zoology (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para tratar condiciones cerebrales. En algunas modalidades, los métodos incluyen administrar a un sujeto que sufre de o es susceptible a una condición cerebral un péptido de angiotensina (1-7) por vía de una ruta de administración ya sea intravenosa o subcutánea.
MX2015003968A 2012-10-02 2013-10-02 Angiotensina en el tratamiento de condiciones cerebrales. MX366134B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261708793P 2012-10-02 2012-10-02
US201261720299P 2012-10-30 2012-10-30
PCT/US2013/062969 WO2014055591A1 (en) 2012-10-02 2013-10-02 Angiotensin in treating brain conditions

Publications (2)

Publication Number Publication Date
MX2015003968A MX2015003968A (es) 2016-02-05
MX366134B true MX366134B (es) 2019-06-28

Family

ID=49919223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003968A MX366134B (es) 2012-10-02 2013-10-02 Angiotensina en el tratamiento de condiciones cerebrales.

Country Status (11)

Country Link
US (4) US8633158B1 (es)
EP (1) EP2903605B1 (es)
JP (2) JP6302916B2 (es)
KR (1) KR20150067228A (es)
CN (1) CN104837485A (es)
AU (2) AU2013327453A1 (es)
CA (1) CA2885912A1 (es)
ES (1) ES2689781T3 (es)
MX (1) MX366134B (es)
RU (2) RU2661109C2 (es)
WO (1) WO2014055591A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
WO2015002903A1 (en) * 2013-07-03 2015-01-08 Arizona Board Of Regents For The University Of Arizona Method for treating cognitive dysfunction
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
WO2016010844A1 (en) * 2014-07-14 2016-01-21 Tarix Pharmaceuticals Ltd Methods and compositions for the treatment of stroke
US10183055B2 (en) 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
JP6666899B2 (ja) 2014-07-21 2020-03-18 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法
CN106699843B (zh) * 2015-07-13 2020-07-28 首都医科大学 RGDVGRPAK-The十肽，其制备，活性及应用
CN106699844B (zh) * 2015-07-13 2020-07-03 首都医科大学 The-RGDVGRPAK十肽，其制备，活性及应用
EP3565824A2 (en) * 2017-01-09 2019-11-13 ARIZONA BOARD OF REGENTS on behalf of THE UNIVERSITY OF ARIZONA Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments
CN109553658B (zh) * 2018-12-13 2022-10-04 重庆大学 Ang-(1-7)的氮杂多肽类似物、制备方法及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
SU1067796A1 (ru) 1981-10-30 1986-01-15 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Циклический аналог ангиотензина,обладающий способностью ингибировать прессорное и миотропное действие ангиотензина
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
DK0730465T3 (da) 1993-09-24 2002-04-08 Univ Southern California Anvendelse af angiotensin III og analoger dertil til vævsreparation
ATE473995T1 (de) 1993-09-24 2010-07-15 Univ Southern California Verwendung von angiotensin-ii-analogen zur gewebewiederherstellung
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
AU722985B2 (en) 1996-07-12 2000-08-17 Mcgill University Compounds and methods for modulating cell adhesion
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US5917151A (en) 1997-08-29 1999-06-29 Ut Automotive Dearborn, Inc. Multi-shot molds for manufacturing wire harnesses
SG92610A1 (en) 1997-10-24 2002-11-19 Univ Singapore The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
AU1706399A (en) 1997-11-26 1999-06-15 University Of Southern California Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1999040106A2 (en) 1998-02-09 1999-08-12 University Of Southern California Use of angiotensin analogues for promoting erythropoiesis
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
EP1061937A1 (en) 1998-03-10 2000-12-27 University Of Southern California Improved radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
AU3077299A (en) 1998-03-11 1999-09-27 University Of Southern California Method of promoting production of living tissue equivalents
AU752041B2 (en) 1998-04-09 2002-09-05 University Of Southern California Methods for treatment and prevention of infections
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
US6475988B1 (en) 1998-05-11 2002-11-05 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
JP3686335B2 (ja) 1998-07-13 2005-08-24 ユニヴァースティ オブ サザーン カリフォルニア 骨および軟骨成長と修復を促進する方法
AU755943B2 (en) 1998-08-13 2003-01-02 University Of Southern California Methods to increase blood flow to ischemic tissue
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
AU756156B2 (en) 1999-03-23 2003-01-02 University Of Southern California Methods for limiting scar and adhesion formation
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
MXPA02005993A (es) 1999-12-16 2002-10-23 Univ Southern California Metodos para tratar y prevenir el dano al tejido epitelial mucoso.
WO2001044270A2 (en) 1999-12-16 2001-06-21 University Of Southern California Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
WO2001098325A1 (en) 2000-06-19 2001-12-27 University Of Southern California Methods for treating and preventing alopecia
US6747008B1 (en) 2000-06-19 2004-06-08 University Of Southern California Methods for treating and preventing alopecia
WO2002087504A2 (en) 2001-05-01 2002-11-07 University Of Southern California Methods for inhibiting tumor cell proliferation
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
AU2002364381A1 (en) 2001-11-23 2003-06-10 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
DE10306179A1 (de) * 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008130217A1 (en) 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
AT506258A1 (de) 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
EP2077119A1 (de) 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
BRPI0800585B8 (pt) * 2008-02-13 2021-05-25 Univ Minas Gerais composições farmacêuticas do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7) e uso do peptídeo des-[asp1]-[ala1]-angiotensina-(1-7)
WO2009114461A2 (en) 2008-03-10 2009-09-17 University Of Southern California Angiotensin (1-7) dosage forms and uses thereof
AT506632A1 (de) 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
EP2163259B1 (en) 2008-09-12 2012-06-13 Charité-Universitätsmedizin Berlin (Charité) Use of an Ang-(1-7) receptor agonist in acute lung injury
CL2008003736A1 (es) 2008-12-15 2009-05-29 Univ Pontificia Catolica Chile Uso de angiotensina (1-9) para preparar un medicamento, util para prevenir, revertir y/o disminuir el remodelado cardiovascular, pulmonar, renal y/o cerebral.
RU2011138165A (ru) 2009-02-17 2013-03-27 Зигнис Байосайенс Гмбх Унд Ко. Кг Применение g-csf для удлинения периода "терапевтического окна" тромболитического лечения инсульта
EP2455388A1 (en) * 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN104394878A (zh) 2012-02-10 2015-03-04 塔瑞克斯制药有限公司 用于治疗周围血管疾病的组合物和方法
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke

Also Published As

Publication number Publication date
RU2661109C2 (ru) 2018-07-11
ES2689781T3 (es) 2018-11-15
AU2018205186B2 (en) 2020-04-09
US20170258766A1 (en) 2017-09-14
US20140094497A1 (en) 2014-04-03
JP2018090625A (ja) 2018-06-14
JP6302916B2 (ja) 2018-03-28
CN104837485A (zh) 2015-08-12
EP2903605A4 (en) 2016-03-23
CA2885912A1 (en) 2014-04-10
EP2903605B1 (en) 2018-08-15
US9511055B2 (en) 2016-12-06
KR20150067228A (ko) 2015-06-17
AU2018205186A1 (en) 2018-08-02
AU2013327453A1 (en) 2015-04-09
EP2903605A1 (en) 2015-08-12
JP6472914B2 (ja) 2019-02-20
MX2015003968A (es) 2016-02-05
US8633158B1 (en) 2014-01-21
RU2018120387A (ru) 2018-11-15
JP2015532291A (ja) 2015-11-09
US20190000809A1 (en) 2019-01-03
WO2014055591A1 (en) 2014-04-10
RU2015110114A (ru) 2016-11-27

Similar Documents

Publication Publication Date Title
MX366134B (es) Angiotensina en el tratamiento de condiciones cerebrales.
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2013010376A (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
IN2015DN01156A (es)
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
EP4414376A3 (en) Novel depsipeptide and uses thereof
MX350378B (es) Mejora del transporte de moleculas terapeuticas a traves de la barrera hematoencefalica.
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
WO2014052360A3 (en) Glycoprotein preparations
MX2013004061A (es) Analogos de ciclosporina.
MY191932A (en) Chitosan-derived compositions
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
MX2021002513A (es) Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.
MY172699A (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MD20140123A2 (ro) Agenţi terapeutici optimizaţi pentru administrare subcutanată
MX2013004062A (es) Analogos de ciclosporina.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
GB201013785D0 (en) Treatment
GB201115977D0 (en) Neurodevelopmental disorders
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.

Legal Events

Date Code Title Description
FG Grant or registration